Back to articles

Aspirin may not be a good option for primary prevention in diabetes


The benefits of low-dose aspirin in preventing serious vascular events in patients with diabetes and no evidence of cardiovascular (CV) disease did not outweigh the risk of major bleeding, according to results of the ASCEND trial published in the New England Journal of Medicine.


ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;[Epub ahead of print].

American Diabetes Association. Standards of Medical Care in Diabetes–2018. Accessed October 13, 2018.

Recent Articles